The FDA committee voted in favor of the Moderna COVID-19 EUA vaccine
17 December 2020 – Moderna’s COVID-19 messenger RNA (mRNA) vaccine candidate, mRNA-1273, today received favorable recommendations from the advisory committee for the US Food and Drug Administration (FDA). The OK Committee means that mRNA-1273 may receive emergency use authorization (EUA) within a few days.
The new immunotherapy supports the polio vaccine to treat cancer
17 December 2020 – As if we needed another reason to get vaccinated, researchers have developed technology that uses the polio vaccine to help treat cancer in those who later develop the disease. The technology, developed at Duke University and developed by Istari Oncology, uses the antigen produced by the polio vaccine to trigger the immune system to eat away at targeted cancer cells.
The genes provide new targets for COVID-19 therapy
15 December 2020 – Genes linked to antiviral immunity and lung inflammation have been linked to severe cases of COVID-19 in a new genome analysis carried out in the UK. The result, published in Natural on December 11, revealed new therapeutic targets for drug reuse and development efforts.
Global health R&D has stalled as resources shifted to COVID-19
December 14, 2020 – The current coronavirus pandemic has slowed progress in research and development (R&D) on neglected diseases and other long-term global health challenges by disrupting ongoing research and directing resources to the work of COVID-19, according to a new report released on December 11. by the nonprofit Global Health Technologies Coalition.
The FDA issued the EUA for Pfizer’s vaccine, BioNTech COVID-19
12 December 2020 – The US Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine. This step comes after the FDA’s Vaccines and Biological Products Advisory Committee issued positive recommendations for the vaccine.
Google’s DeepMind is making a quantum leap in solving the problem of protein folding
11 December 2020 – Artificial intelligence has made breakthroughs in protein structure prediction. The results come as part of the 14th Critical Assessment of Structure Prediction, a friendly contest and conference organized by the Protein Structure Prediction Center with sponsorship from the National Institute of General Medical Sciences, part of the US National Institutes of Health.
The FDA committee approved the transfer of Pfizer, the BioNTech COVID-19 vaccine to EUA
December 10, 2020 – Pfizer-BioNTech’s COVID-19 vaccine candidate, BNT162b2, passed an important milestone today when the US Food and Drug Administration (FDA) advisory committee determined that the candidate’s benefits in preventing COVID-19 outweigh the risks. The committee’s advice is likely to lead to the issuance of an emergency use authorization (EUA) for vaccines by the FDA within days.
The new study found the SARS-CoV-2 antibodies disappeared rapidly
8 December 2020 – Antibodies developed after being infected with the SARS-CoV-2 virus disappeared rapidly, according to an analysis published in Immunology Science on December 7th. These findings may suggest that SARS-CoV-2 infection may not offer long-term immunity from subsequent reinfection with the virus.
The new universal flu vaccine targets conserved areas of viral surface proteins
December 7, 2020 – A new universal influenza vaccine has been developed that targets the surface protein stem of the influenza virus rather than the head. This vaccine, which is capable of neutralizing various strains of influenza, was evaluated in a phase I clinical study whose results were published in Natural Medicine on December 7th.
Regulatory Roundup: The appointment is made before the end of the year
December 7, 2020 – This week’s Regulatory Roundup covers activities from November 30 to December 4 and is filled with breakthroughs, orphans, and rare disease appointments from the US Food and Drug Administration and the European Medicines Agency. Several cancer, immunotherapy, and vaccine companies also submitted biological licensing applications to advance their candidates.
to request modification Contact us at Here or [email protected]